Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GAIN THERAPEUTICS, INC.

(GANX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
7.62(c) 7.24(c) 7.04(c) 6.75(c) 6.52 Last
43 164 78 559 97 648 95 703 113 216 Volume
-2.93% -4.99% -2.76% -4.12% -3.41% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 0,15 M - -
Net income 2021 -16,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,02x
Yield 2021 -
Sales 2022 0,11 M - -
Net income 2022 -26,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,49x
Yield 2022 -
Capitalization 110 M 110 M -
Capi. / Sales 2021 737x
Capi. / Sales 2022 1 013x
Nbr of Employees 13
Free-Float 69,5%
More Financials
Company
Gain Therapeutics, Inc. is a holding company. The Company, through its subsidiary, GT Gain Therapeutics SA, is a development stage biotechnology company. The Company is focused on developing therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. It uses its platform, Site-Directed Enzyme... 
More about the company
All news about GAIN THERAPEUTICS, INC.
12/01Gain Therapeutics to Participate at the Imagine AI + Healthcare Investor Summit
GL
11/12GAIN THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
11/12Gain Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Business Updat..
PU
11/12Earnings Flash (GANX) GAIN THERAPEUTICS Reports Q3 Revenue $27,345
MT
11/12Gain Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Business Updat..
AQ
11/11Gain Therapeutics Presents Parkinson's Disease Preclinical Study Results at Society for..
GL
11/11Gain Therapeutics, Inc. Presents Parkinson?s Disease Preclinical Study Results at Socie..
CI
11/10Gain Therapeutics, Inc. Announces Breakthrough Pre-Clinical Dataáof Novel Small Molecul..
GL
11/10Gain Therapeutics, Inc. Announces Breakthrough Pre-Clinical Data?of Novel Small Molecul..
CI
11/04Gain Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference
AQ
11/03B. Riley Starts Gain Therapeutics at Buy with $21 PT, Encouraged by Drug Discovery Appr..
MT
10/28Gain Therapeutics to Present at Upcoming Medical Conferences
GL
10/26Gain Therapeutics, Inc. Announces Appointment of Five Members to its Newly Formed Scien..
AQ
10/26Gain Therapeutics, Inc. Announces Appointment of Five Members to Its Newly Formed Scien..
CI
10/20GAIN THERAPEUTICS : Appoints Matthias Alder as Chief Operating Officer - Form 8-K
PU
More news
News in other languages on GAIN THERAPEUTICS, INC.
11/12Earnings Flash (GANX) GAIN THERAPEUTICS annonce un chiffre d'affaires de 27 345 $ pour ..
09/08Gain Therapeutics déclare que les premières données montrent les " effets positifs " du..
08/11Earnings Flash (GANX) GAIN THERAPEUTICS annonce un chiffre d'affaires de 89 173 $ pour ..
06/10Gain Therapeutics obtient deux brevets couvrant des composés pour les troubles du systè..
More news
Analyst Recommendations on GAIN THERAPEUTICS, INC.
More recommendations
Chart GAIN THERAPEUTICS, INC.
Duration : Period :
Gain Therapeutics, Inc. Technical Analysis Chart | GANX | US36269B1052 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 6,52 $
Average target price 27,00 $
Spread / Average Target 314%
EPS Revisions
Managers and Directors
Eric I. Richman Chief Executive Officer & Director
Manolo Bellotto President & General Manager
Salvatore Calabrese Chief Financial Officer
Khalid Islam Chairman
Xavier Barril Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GAIN THERAPEUTICS, INC.0.00%110
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
IQVIA HOLDINGS INC.46.64%50 192
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-41.36%24 745